2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2131

Prevalence of Systemic Lupus Erythematosus (SLE) and Associated Comorbidities in the 2011-2015 Medicare Population
Abstract Number: 2132

All-Cause Mortality, Hospitalization, and Systemic Lupus Erythematosus (SLE) Related Complications in 2011-2015 Medicare Beneficiaries with SLE
Abstract Number: 2133

Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Abstract Number: 2134

Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis
Abstract Number: 2135

Identification of Psoriatic Arthritis Using an Administrative Claims-Based Algorithm
Abstract Number: 2136

Mortality Rates and Causes in Psoriatic Arthritis Patients
Abstract Number: 2137

Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults
Abstract Number: 2138

Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis
Abstract Number: 2139

Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Abstract Number: 2140

Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Rheumatoid Arthritis: A Retrospective Study
Abstract Number: 2141

Development of a Pediatric Glucocorticoid Toxicity Index
Abstract Number: 2142

Exposure to Disease Modifying Antirheumatic Drugs during Pregnancy in Women with Inflammatory Arthritis and the Risk of Serious Maternal Infection: A Population-Based Cohort Study
Abstract Number: 2143

Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
Abstract Number: 2144

Epidemiological Characterisitics of Psoriatric Arthritis: A Nationwide Study of Inpatient Hospitalisations in 2014
Abstract Number: 2145

Increased Risk of Heart Failure with Prolonged Use of Hydroxychloroquine in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].